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In Brief
The PhenoGraph algorithm robustly
partitions high-parameter single-cell data
into phenotypically distinct
subpopulations, aiding the study of
complex tissues and disease cohorts.
Applying PhenoGraph to a pediatric
acute myeloid leukemia dataset revealed
a recurrent population of leukemic cells
with variable cell surface markers, but
consistent signaling dynamics that
mimicked normal hematopoietic
progenitors.
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Acute myeloid leukemia (AML) manifests as pheno-
typically and functionally diverse cells, often within
the same patient. Intratumor phenotypic and func-
tional heterogeneity have been linked primarily by
physical sorting experiments, which assume that
functionally distinct subpopulations can be pros-
pectively isolated by surface phenotypes. This
assumption has proven problematic, and we there-
fore developed a data-driven approach. Using
mass cytometry, we profiled surface and intracellular
signaling proteins simultaneously in millions of
healthy and leukemic cells. We developed Pheno-
Graph, which algorithmically defines phenotypes in
high-dimensional single-cell data. PhenoGraph re-
vealed that the surface phenotypes of leukemic
blasts do not necessarily reflect their intracellular
state. Using hematopoietic progenitors, we defined
a signaling-based measure of cellular phenotype,
which led to isolation of a gene expression signature
that was predictive of survival in independent co-
horts. This study presents new methods for large-
scale analysis of single-cell heterogeneity and dem-
onstrates their utility, yielding insights into AML
pathophysiology.INTRODUCTION
Intratumor heterogeneity is accepted to be functionally and
clinically significant (Marusyk et al., 2012). Recent evidence
implies that the pathobiology of cancer results from the ac-
tions and interactions of diverse subpopulations within the tu-
mor. Thus, it is necessary to study tumors with methods that
preserve single-cell resolution. Emerging technologies such
as mass cytometry (Bendall et al., 2011) and single-cell184 Cell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc.RNA-seq (Patel et al., 2014) have attained dramatic increases
in dimensionality and throughput, bringing unprecedented
resolution to the diversity of cellular states detectable in a
given tissue. Yet, to take advantage of these technological
gains, computational methods are required to robustly iden-
tify high-dimensional phenotypes and compare them within
and between individuals. Data-driven phenotypic dissection
may then form the basis for downstream analyses in which
subpopulations are isolated and compared, revealing the
role of population structure in complex systems such as
malignancies.
Intratumor heterogeneity is pervasive in acute myeloid leu-
kemia (AML), an aggressive liquid tumor of the bone marrow
characterized by an overwhelming abundance of poorly differ-
entiated myeloid cells (‘‘blasts’’). Arising from the disruption of
regulated myeloid differentiation (Tenen, 2003), AML results in
a disordered developmental hierarchy wherein leukemic stem
cells (LSCs) are capable of re-establishing the disease in
immunodeficient mice (Bonnet and Dick, 1997). LSCs were
first thought to be restricted to the same CD34+/CD38– cellular
compartment as normal hematopoietic stem cells (HSCs).
Subsequent studies have demonstrated that both CD38+
(Taussig et al., 2008) and CD34– (Taussig et al., 2010) AML
blasts can have LSC capacity, indicating that AML does not
follow the hierarchy of normal hematopoiesis. While AML
exhibits a differentiated hierarchy, no uniform phenotypic
identifier for LSCs has been found across patients (Eppert
et al., 2011).
Recognizing a disconnect between functionally primitive (e.g.,
tumor-initiating) cells associated with cancer persistence and
their surface phenotype, we simultaneously examined surface
antigen expression and regulatory signaling in individual AML
cells. We reasoned that intracellular signaling rather than surface
antigen profile more accurately represents the functional state of
a diseased cell. We used mass cytometry to measure protein
expression and activation state in millions of cells from AML pa-
tients and healthy bone marrow donors in 31 simultaneous di-
mensions. By measuring cells after ex vivo perturbations, we
further expanded the dimensionality of the data by revealing
functional responses to environmental cues, reflecting the
broader cellular network beyond what can be inferred from the
unperturbed state (Irish et al., 2004). To avoid the pitfalls of
manual gating, we developed PhenoGraph, a robust computa-
tional method that partitions high-dimensional single-cell data
into subpopulations. Building on these subpopulations, we
developed additional methods to extract high-dimensional
signaling phenotypes and infer differences in functional potential
between subpopulations.
Our data-driven approach revealed two new perspectives
on the pathobiology of AML. First, we found that pediatric
AML draws from a surprisingly limited repertoire of surface
phenotypes, indicating some memory of normal myelopoiesis.
Despite genetic diversity, patterns of surface antigen expres-
sion followed trends in myeloid development, indicating limits
in the ability of leukemic cells to phenotypically diverge from
normal antigen profiles. Second, we found that the signaling
pattern of undifferentiated hematopoietic progenitors defined
a primitive signaling phenotype that was recapitulated in a ma-
jority of AML samples at varying frequencies. Functionally
primitive leukemic cells—defined by signaling—were not
linked to a consistent surface phenotype, including the stan-
dard HSC/LSC antigen profile (i.e., CD34+/CD38–), demon-
strating that surface antigens are decoupled from regulatory
networks in leukemia. The frequency of these functionally
primitive cells enabled isolation of a gene expression signature
that was enriched for stem cell annotations and formed a sig-
nificant predictor of overall survival in independent AML clin-
ical cohorts.
Taken together, we provide an alternative paradigm for identi-
fying primitive cancer cells that complements the immunophe-
notypic definitions of cancer stem cells traditionally used in
both AML and other systems. Moreover, this analysis framework
is robust and broadly applicable to the characterization of
subpopulation structure and function from single-cell data in a
wide range of systems.
RESULTS
High-Dimensional Single-Cell Profiling of Pediatric AML
by Mass Cytometry
We usedmass cytometry to obtain single-cell proteomic profiles
of cryopreserved bone marrow aspirates from pediatric AML pa-
tients obtained at diagnosis (n = 16) and from healthy adult
donors (n = 5). We performed preliminary analysis to select 16
highly informative surface markers that efficiently captured the
intra- and intertumor heterogeneity in our cohort (Supplemental
Experimental Procedures). We added 14 antibody probes
against intracellular phosphorylation, thus allowing simulta-
neous measurement of surface phenotype and signaling
behavior in single cells. Each sample was subjected ex vivo to
a battery of short-term molecular perturbations (cytokines and
chemical inhibitors; Table S1) to elicit functionally relevant
signaling responses (Bendall et al., 2011; Irish et al., 2004).
The complete dataset contained over 15 million single cells
from 21 individuals measured in 31 simultaneous protein
epitope dimensions following exposure to one of 17 conditions
(Figure 1A).PhenoGraph Dissects Population Structure in High-
Dimensional Single-Cell Data
Complex tissues such as bone marrow are composed of bio-
logically meaningful subpopulations that are phenotypically
coherent despite the intrinsic variability that makes each cell
unique. A fundamental challenge is to establish themajor pheno-
types present, enabling an efficient and meaningful profile of the
tissue. While normal immune cells are typically binned into pre-
defined ‘‘landmark’’ cell subsets, this strategy is unsuitable for
less predictable or under-studied tissues such as cancer, where
new phenotypes have been shown to occur. Thus a data-driven,
unsupervised approach is needed that takes single-cell mea-
surements and returns a grouping of cells into distinct subpopu-
lations (i.e., clusters).
Dimensionality reduction techniques such as t-distributed sto-
chastic neighbor embedding (t-SNE) (Amir et al., 2013; Maaten
and Hinton, 2008) help visualize the data but do not explicitly
identify and partition cells into subpopulations. Moreover, not
all subpopulations are visually distinct when rendering high-
dimensional data in only two dimensions. We evaluated a num-
ber of leading methods for clustering fluorescence cytometry
data and found that these did not perform well for mass cytom-
etry data (Aghaeepour et al., 2013). Parametric methods (Pyne
et al., 2009) require strong assumptions about the high-dimen-
sional shape of cellular populations (e.g., ellipsoid, convex),
which are violated in single-cell data (Amir et al., 2013). Therefore
a non-parametric approach is needed, yet these currently use
unstable heuristics or suffer from computational inefficiency
and do not scale well to higher dimensions. We found that as
the number of dimensions increased, available methods
routinely failed to correctly identify known subsets, gave incon-
sistent results and were prohibitively slow (Supplemental Exper-
imental Procedures).
To robustly discover subpopulations in high-dimensional
single-cell data, we developed PhenoGraph. The parameters
measured for each cell define a point in high-dimensional space
wherein clustering is tantamount to finding dense regions. The
difficulty is that density detection in high dimensions is both
computationally hard and statistically unstable. Following our
previous work (Bendall et al., 2014), we model this high-dimen-
sional space using a nearest-neighbor graph. In this graph,
each cell is represented by a node and connected by a set of
edges to a neighborhood of its most similar cells. The graph
distills the high-dimensional distribution of single cells into a
compact, information-rich data structure that captures pheno-
typic relatedness and overcomes many pitfalls of standard
geometries.
After the nearest-neighbor graph is constructed, the problem
of density detection corresponds to the task of finding sets of
highly interconnected nodes (Figure 1B). To this end, we borrow
from the social network field, which has developed powerful al-
gorithms to partition large social networks into communities (Gir-
van and Newman, 2002). In our setting, communities represent
an accumulation of phenotypically similar cells that likely reflects
biologically meaningful phenotypic stability, thus revealing sta-
ble cellular states in the population. Partitioning the graph into
these communities produces a dissection of the population
into phenotypically coherent subpopulations. CommunityCell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc. 185
Figure 1. Mass Cytometry Analysis of Signaling Responses in Pediatric Acute Myeloid Leukemia
(A) Summary of experimental design.
(B) PhenoGraphmethod for clustering high-dimensional single-cell data. Each node in the neighbor graph represents one of 500 random cells from healthy donor
H1 colored by CD34 expression. CD34+ HSPCs form a dense subgraph and are automatically assigned to a single subpopulation. See Figure S1 and Experi-
mental Procedures for more details on the PhenoGraph algorithm.
(C) HSPCs identified by PhenoGraph fromdonor H1. This subpopulation (red histograms) had a CD34+/CD45low phenotype relative to the other cells in the sample
(gray histograms). Each PhenoGraph subpopulation contained cells from all perturbations, permitting analysis of 224 signaling responses.detection algorithms make no assumption about the size, num-
ber, or form of subpopulations (Fortunato, 2010). Importantly,
communities need not be convex, symmetric, or ellipsoid—as-
sumptions that are questionable for complex cellular popula-
tions. Efficient implementations can partition large graphs in
minimal computation time (Blondel et al., 2008).
A key step in the PhenoGraph method is converting the sin-
gle-cell data to a graph that faithfully represents the phenotypic186 Cell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc.relationships between cells. Without a carefully constructed
graph, large populations can obscure rare ones (which may
be outnumbered by orders of magnitude). This problem is
further exacerbated by measurement noise that can spuriously
link unrelated parts of the graph. We addressed both problems
by constructing the graph in two iterations, using the Jaccard
similarity coefficient in the second iteration. Thus, the similarity
between cells is redefined by the number of shared neighbors
Figure 2. PhenoGraph Clustering Recapitulates Manual Assignments of Healthy Immune Cells
(A) viSNE (Amir et al., 2013) display of 30,000 cells from healthy BMMC benchmark data (Bendall et al., 2011). Cells are colored by cell-type assignments
established by manual gating (left) or subpopulations detected by PhenoGraph (right).
(B) Comparison of PhenoGraph to othermethods on the benchmark dataset, assessed for ability to recover themanual cell-type assignments quantified using the
F-measure statistic (Aghaeepour et al., 2013) and normalized mutual information (Figure S2C). Box plots (generated by MATLAB’s ‘‘boxplot’’ function) show the
distributions of F-measure computed from 50 random samples of 20,000 cells from the full dataset. PhenoGraph was tested with four different settings of its
single parameter k. Small interquartile ranges demonstrate that PhenoGraph accurately identifies the structure of the original population and is robust to random
subsampling and to choice of parameter k. Comparison on additional benchmark datasets is provided in Data S1G–S1I.following the first iteration (see Experimental Procedures and
Figure S1). The Jaccard metric exploits the local density at
each data point, removing spurious edges and strengthening
well-supported ones. The co-occurrence of rare cells in the
same phenotypic vicinity produces strongly interconnected
modules that distinguish these rare cells from noise. Overall,
the modular nature of the population is better revealed in the re-
sulting graph.
Healthy human bone marrow, which is rich in distinct and
well-characterized immunological cell types, presents a
benchmark case for phenotypic dissection. We tested Pheno-
Graph on three different mass cytometry datasets of healthyhuman bone marrow (Bendall et al., 2011) and PhenoGraph
correctly identified labeled immune cell types, displaying supe-
rior precision, recall, and robustness against leading methods
(Aghaeepour et al., 2013) (Supplemental Experimental Proce-
dures and Figures 2 and S2A–S2C, and Data S1). PhenoGraph
runs efficiently on large datasets with substantially better
scaling than other methods (Figure S2D) and can process mil-
lions of cells with modest computational resources. Pheno-
Graph is able to resolve subpopulations as rare as 1/2,000
cells and is robust to random subsampling and to the choice
of the single user-defined parameter (Figures 2 and S2A–
S2C, and Data S1).Cell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc. 187
Figure 3. Intra- and Intertumor Heterogene-
ity Is Visible across the Phenotypic Land-
scape of Pediatric AML
(A) t-SNE landscape of average surface marker
expression of non-lymphoid PhenoGraph clusters
from the AML cohort. Each cluster is represented
by a single point scaled to represent its sample
proportion and in the main panel colored by pa-
tient identity. Normal bone marrow cell types (H1-
H5; blue) provide landmarks for interpreting the
phenotypes of the leukemic bonemarrow samples
(SJ01-SJ16). In additional panels each subpopu-
lation is colored bymedian expression of indicated
surface markers.
(B) PhenoGraph applied to cluster centroids
consolidated the 616 patient-level subpopulations
into 14 cohort-level metaclusters (MCs). Stacked
columns indicate the contribution made by each
patient to each MC.
(C) Average surface marker expression in each
MC, summarizing the major phenotypes observed
across the cohort. Columns match those repre-
sented in (B).
(D) Intrapatient heterogeneity for each patient
is represented graphically by a horizontal bar in
which segment lengths represent the proportion
of the patient assigned to each MC, colored
according to the accompanying legend (bottom
right). Hierarchical clustering of these patient de-
scriptions revealed that some patterns of intra-
patient heterogeneity were significantly correlated
with genetic biomarkers. (CBF, core binding tran-
scription factor translocation, p = 0.0014; NPM1,
nucleophosmin mutation, p = 0.0083; CN, cyto-
genetically normal, p = 0.018).Conformity of Phenotypes in the Landscape of AML
After validating PhenoGraph on healthy cells, we applied it to our
pediatric AML cohort. We ran PhenoGraph on each sample indi-
vidually, defining subpopulations based on the 16measured sur-
face markers. This yielded an average of 28 subpopulations per
sample (ranging between 17 and 48), totaling 616 subpopula-
tions across the entire cohort. Subpopulation size varied by or-
ders of magnitude, from 7 3 102 to 2 3 105 cells (or 0.06% to
20%of a sample). For each sample, we pooled data from all con-
ditions, enabling characterization of subpopulation-specific188 Cell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc.signaling patterns. Each resulting sub-
population was a multifaceted data ob-
ject, containing information about surface
phenotypes, as well as the response of
each signaling marker to each molecular
perturbation (Figure 1C).
Each leukemia presented a diversity of
surface phenotypes defined by distinct
combinations of marker expression
(Data S2A). We sought an overview of
the similarities and differences between
detected subpopulations across patients
that could reveal larger trends and enable
direct comparison of all subpopulationssimultaneously. To do so, we began by representing each Phe-
noGraph subpopulation by its surface marker centroid. We
then used t-SNE (Maaten and Hinton, 2008), to reduce the 16-
dimensional data to 2 dimensions, following an approach previ-
ously taken with cytometry data (Amir et al., 2013). The resulting
2D landscape provided an intuitive and comprehensive overview
of the major phenotypes present in the cohort and also demon-
strated the extent of intra- and intertumoral heterogeneity or sim-
ilarity (Figure 3A). Subpopulations from healthy and leukemic
samples were mapped simultaneously so the healthy cell types
could act as ‘‘landmarks’’ to aid interpretation of the leukemic
subpopulations. Normal lymphoid cell types were excluded
from the landscape (Supplemental Experimental Procedures)
to focus on primitive and myeloid phenotypes, ‘‘zooming in’’
on the myeloid lineages relevant to AML.
The AML cohort landscape organized the subpopulations into
regions of phenotypic similarity, distinguished by particular
marker combinations. Inspecting the structure of this landscape,
we found that the vertical axis largely mimicked trends in normal
myeloid development with primitive markers expressed toward
the top and more mature markers toward the bottom (Figure 3A
and Data S2B and S2C). Healthy CD34+/CD38mid hematopoietic
stem and progenitor cells (HSPCs) provided the most primitive
landmark, located at the top of the landscape plot. AML subpop-
ulations in this region displayed surface profiles that resembled
the HSPC phenotype. At the bottom of the landscape, the
CD11b+ healthy monocytes served as a landmark for differenti-
ated myeloid cells, representing full maturation not observed in
the leukemic samples. Between these two poles, other devel-
opingmyeloid antigens—CD38, CD117, CD123, CD33—peaked
and subsided, thus the vertical axis of the landscape resembled
normal myeloid development (Data S2B and S2C). The adher-
ence of AML phenotypes to this axis suggests that myeloid
developmental programs continue to influence the phenotypic
diversity of leukemic cells even after malignant transformation.
The patterns of intratumor heterogeneity support this view, as
most patients contained a mixture of ‘‘primitive’’ and ‘‘mature’’
surface phenotypes (Data S2D).
Metaclusters Highlight Interpatient Similarity
Despite the widespread phenotypic diversity observed within
patients (Data S2E), the cohort landscape revealed a surprising
conformity when comparing AML subpopulations across
different patients. Multiple patients occupied each phenotypic
region in the landscape and no patient presented a substantially
unique phenotype, suggesting that subpopulations could be
matched across patients, cohort-wide. To examine these
cohort-level phenotypes further, we pursued a metaclustering
approach in which subpopulations from each patient were
merged by a secondary clustering analysis (Pyne et al., 2009).
We represented each AML subpopulation by its centroid and
used PhenoGraph to group centroids into metaclusters (MCs;
see Experimental Proceduresand Figure S3A), identifying 14
MCs that delineated the major cohort phenotypes (Figure 3B-
C). Each MC had a mixed patient composition, containing sub-
populations from at least 2 patients and a median of 11 patients.
To evaluate the robustness of these MCs, we performed
cross-validation and observed high reproducibility (Figure S3B
and Supplemental Experimental Procedures). Subsequently,
we used the healthy samples (H1–H5) to interpret the MCs by
systematically matching cells from healthy bone marrow with
theMC surfacemarker profiles (Supplemental Experimental Pro-
cedures). Several MCs corresponded clearly to non-malignant
cell types (constituting a small proportion of each leukemic sam-
ple), while the remaining MCs represented presumptive blast
phenotypes. We determined that 7/14 MCs represented malig-
nant expansions (MC 1–4, 6, 7, 13), based on the relative fre-
quency of healthy cognates (Figure 3B) and surface marker pro-files (Figure 3C). As expected from the histopathology of AML,
the blast phenotypes resembled normal primitive and progenitor
phenotypes with a myeloid bias. Each malignant phenotype was
detected in multiple patients, but only MC13 was detected in all
patients. The CD64+/HLA-DR+ expression profile of MC13 indi-
cates an immature monocytic phenotype that was often drasti-
cally more abundant in AML than in healthy samples. Occupancy
in MC13 varied substantially between patients (0.8%–77%),
consistent with a model of AML as a block in myeloid differenti-
ation with variable severity (Tenen, 2003).
Samples were evaluated quantitatively in terms of their pro-
portional occupancies of the 14 MCs (Figure 3D). As expected,
the five healthy samples were similar to each other and distinct
from AML. Interestingly, MC occupancies organized the AML
samples into subgroups that were significantly correlated with
other molecular biomarkers (Figure 3D). For example, patients
with core binding factor translocation [t(8;21) or inv(16)] had large
numbers of cells in MC4 and MC13, placing them in a group en-
riched for this clinical annotation (p = 0.0014, hypergeometric
test). Patients with nucleophosmin mutations displayed a
different phenotypic distribution—occupancy of MC2, MC7
and MC13—forming another distinct patient group (p =
0.0083). Finally, the three patients characterized by large occu-
pancies of MC1 were all cytogenetically normal (p = 0.018).
Taken together, each leukemia, although unique, appears to
be formed from a limited palette of possible phenotypes.
Remarkably, the specific composition and relative proportion
of MCs was determined in part by genetic background, demon-
strating a genetic influence on the distribution of phenotypes
observed in each patient.
Signaling Phenotypes Define Functionally Distinct
Subpopulations
Surface markers have become standard tools for clinical diag-
nosis and monitoring of blood neoplasia (Craig and Foon,
2008). In normal bone marrow, cell surface markers identify
stem and progenitor cell populations with distinct lineage poten-
tial and intracellular signaling behaviors (Bendall et al., 2011).
However, in AML, no surface marker phenotype has been estab-
lished that consistently distinguishes the more primitive blasts
universally across patients (Eppert et al., 2011; Taussig et al.,
2008; 2010).
We hypothesized that intracellular signaling might be a better
surrogate of the underlying functional potential and therefore
included molecular perturbations known to elicit signaling re-
sponses that are functionally relevant to normal and malignant
hematopoiesis (Table S1). Intracellular signaling markers were
selected to represent pathways known to be functionally and
clinically relevant in AML, including JAK/STAT, PI3K/AKT, and
MAPK. The response of each of 14 signaling proteins to each
of 16 perturbations revealed a facet of the underlying network
that controls cellular function, resulting in 224 signaling re-
sponses per subpopulation. We used these data to build a
quantitative signaling phenotype representing the structure
and function of the intracellular signaling network in each
subpopulation.
To fully harness the single-cell nature of our data, we devel-
oped SARA (Statistical Analysis of Perturbation Response; seeCell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc. 189
Figure 4. Analysis of Perturbation
Response Generates Signaling Phenotypes
(A) An illustration depicting how SARA uses the
single-cell distributions together with permutation
testing to score signaling response.
(B) SARA, applied to every signaling molecule for
every perturbation in every subpopulation, pro-
duced138,000 responses, which were compiled
into 224-dimensional signaling phenotypes (col-
umns) for each of the 616 subpopulations (rows).
Rows and columns ordered by agglomerative
linkage.
(C) Hierarchical clustering of four developmentally
relevant signaling responses in the healthy sam-
ples (top) identified patterns of primitive signaling
(PS) and mature signaling (MS) correlated with
expression of CD34 and CD45, in the healthy
samples. Hierarchical clustering of the same
signaling responses in the AML samples (bottom)
identified a cluster of subpopulations that reca-
pitulated the primitive signaling pattern, but lacked
a consistent surface phenotype. Color scales are
as in Figures 3A and 4A.
(D) Box plots comparing CD34 expression be-
tween signaling clusters identified in (C). CD34
expression was significantly associated with
primitive signaling only in the healthy samples. The
box plots are generated by MATLAB’s ‘‘boxplot’’
function, using default settings.Experimental Procedures and Figure 4A). SARA examines the
entire single-cell distribution of phosphoprotein intensities to
detect meaningful changes between two conditions. SARA in-
corporates a measure of statistical significance through permu-
tation testing, producing estimates that are sensitive to small
responsive subsets yet robust to sampling error and noise.
Together, PhenoGraph and SARA distilled high-dimensional
data for 15 million cells into a single matrix of subpopulations
and their signaling phenotypes (Figure 4B), revealing a rich vari-
ety of signaling potential across subpopulations.
Within the healthy samples, surface and signaling phenotypes
were tightly coupled, consistent with previous reports (Bendall
et al., 2011; Gibbs et al., 2011). Hierarchical clustering of a
curated set of progenitor- and lineage-associated signaling fea-
tures produced a complete separation of primitive (CD34+) and
mature (CD34–) cell types among the healthy samples (Figures
4C and 4D; p = 2.0 3 1052, Student’s t test). In the leukemic
samples, the same procedure produced a similar stratification
of signaling phenotypes, including a set of subpopulations that190 Cell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc.recapitulate the signaling profile of
healthy primitive cells. However, this
stratification of primitive (PS) and mature
(MS) signaling had no association with
CD34 expression (p = 0.83, Student’s t
test; Figure 4D). Decoupling of surface
and signaling phenotypes in the leukemic
samples is consistent with evidence that
surface markers are unreliable proxies
of cellular function in AML (Eppert et al.,
2011; Gibbs et al., 2011; Taussig et al.,2008; 2010). We therefore sought to use signaling phenotypes
rather than surface phenotypes as alternative proxies for func-
tional state.
Classification of Leukemic Maturity by Signaling
Phenotype
PhenoGraph and SARA yielded two alternative representations
for each subpopulation: a 16-dimensional surface phenotype
and a 224-dimensional signaling phenotype (Figure 5A). We
asked if there was a characteristic signaling phenotype of undif-
ferentiated healthy cells that could act as a high-dimensional
generalization of the CD34/CD38 surface phenotype, which
would more faithfully capture the functional aspect of the primi-
tive state.
Harnessing the tight coupling between surface and signaling
in the healthy system, we grounded our analysis in a character-
ization of healthy subpopulations. PhenoGraph metaclustering
of the five normal marrow samples identified 20 healthy cell
types (Figure 5B and Data S3A). Using ANOVA, we examined
Figure 5. Data-Driven Scoring of Leukemic Maturity by Either Surface or Signaling Phenotype
(A) Each PhenoGraph subpopulation has two alternative phenotypes: surface and signaling.
(B) Normal cell types identified in healthy samples display characteristic surface and signaling phenotypes, represented by heat maps. Each row represents the
indicated cell type (Mono = Monocyte). Surface markers (left) and signaling responses (right) are colored as in (A). Signaling responses are ordered from left to
right by decreasing significance of association with cell type (Table S2).
(C) The same t-SNE map presented in Figure 3A, labeled by results of PhenoGraph classification. Colors depict whether a subpopulation was assigned to either,
both, or neither primitive class as determined by signaling (IFPC) or surface (SDPC). (see Figures S4A and S4B).
(D) Frequencies of primitive cells: %IFPC or %SDPC for each patient sample.their signaling profiles for responses that were consistently asso-
ciated with particular cell types and found that a large number
of signaling responses had significant associations with cell
type (Table S2). Many of these were induction responses
specific to undifferentiated cells, including G-CSF/pSTAT3(Q = 6.4 3 1042) and SCF/pAKT (Q = 1.0 3 109), as previ-
ously reported (Gibbs et al., 2011).
We then asked whether cell types could be distinguished
entirely by their signaling phenotypes, rendering surface pheno-
types dispensable for characterizing the subpopulations. To testCell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc. 191
this, we developed a framework for classifying subpopulations
based on either their surface or signaling phenotypes. We
derived an extension of PhenoGraph that uses the same
graph-basedmodel but assigns observations to classes accord-
ing to user-defined training examples (‘‘PhenoGraph classifica-
tion’’; see Experimental Procedures and Figure S4A). First, we
verified that PhenoGraph was capable of recovering ‘‘held out’’
healthy cell-type labels using a graph derived from surface phe-
notypes. Performance was evaluated using the cross-validated
correct classification rate (CCR) and indeed, PhenoGraph
correctly recovered 99.42% of the cell-type labels in this test.
Next, we constructed a graph based only on similarity among
signaling phenotypes, withholding all surface phenotype infor-
mation. Using this graph, PhenoGraph’s ability to recover the
surface-defined labels was modestly diminished (CCR = 94%)
due to errors distinguishing mature cell types for which charac-
teristic signaling phenotypes had not been measured. Focusing
on the task of distinguishing themost primitive cells (i.e., HSPCs)
from the mature cell types, we found that signaling phenotypes
performed equivalently to surface phenotypes (CCR = 99.85%;
see Experimental Procedures).
Considering that signaling phenotypes were sufficient to
distinguish healthy primitive cells, we hypothesized that the
functional state of AML subpopulations could be inferred by
direct examination of their signaling phenotypes. With the
healthy subpopulations as training examples, we used Pheno-
Graph to classify the AML subpopulations, producing an esti-
mate of functional state for each subpopulation (e.g., HSPC-
like or monocyte-like). Because there were two alternative
phenotypes for each subpopulation—surface and signaling—
we performed two separate classifications (Figure S4B). The
result was a data-driven assessment of each AML subpopula-
tion, indicating which healthy cell type it resembled in its surface
marker expression on one hand and in its high-dimensional
signaling phenotype on the other.
Inferred Functional Maturity Diverges from Surface
Phenotype in AML
The classifiers identified primitive subpopulations within each
patient sample, reflecting the heterogeneous nature of the sam-
ples. At the cohort level, each classifier labeled 25% of sub-
populations as primitive, but only 16% were identified as primi-
tive by both classifiers simultaneously (Figure 5C). In many
cases (32/99), subpopulations with primitive surface marker
phenotypes exhibited signaling that resembled mature cells.
Conversely, many subpopulations displayed primitive signaling
in the absence of primitive surface marker expression (51/118).
We denote cells labeled primitive by the surface phenotype
classifier as Surface-Defined Primitive Cells (SDPCs) and cells
labeled primitive by the signaling classifier as Inferred Function-
ally Primitive Cells (IFPCs). For each patient, the sample propor-
tion assigned to each of these labels produced two alternative
measures of maturity (%SDPC or %IFPC; Figure 5D and Table
S2). This is similar to summarizing the degree of maturation by
the enumeration of CD34+/CD45low blasts, a practice often
used in the clinical diagnosis and classification of leukemias
(Craig and Foon, 2008). Indeed, we found that %SDPC was
highly correlated with this standard manual gating procedure192 Cell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc.(Pearson’s r = 0.96, p = 4.4 3 109; Figure S4C and Data
S3B). Conversely, %SDPC was only weakly correlated with %
IFPC (Pearson’s r = 0.5; p = 0.05), demonstrating that these
two metrics are not redundant in AML. Instead, examination of
signaling phenotypes in AML often revealed a different degree
of maturation than was indicated by the surface phenotype.
We noted that the degree of discordance between IFPC and
SDPC assignments was not constant across patients, indicating
that the tendency of IFPCs to express canonical LSC markers
was itself a variable patient feature. For example, the IFPCs in
patient SJ05 were well represented by the CD34+/CD38mid
phenotype (Figure 6, left column). In other cases, IFPCs were
found exclusively in the CD34– fraction, even when CD34+ blasts
were abundant (e.g., SJ16).
Differences in signaling patterns between primitive and mature
leukemic subpopulations reveal the responses most important
for these classifications (Figure 6; see Figure S5A for all patients).
We used canonical variates analysis (Supplemental Experimental
Procedures for details) to quantify this importance, finding
that the majority of discriminative power could be attributed to 5
responses: G-CSF/pSTAT3, SCF/pAkt, G-CSF/pSTAT5,
Flt3-L/pAkt, and IL-10/pSTAT3 (Figure S5B and Table S2).
Primitive subpopulations displayed strong activation in the first
four of these responses,which haveall beenpreviously implicated
in thebiologyofHSPCs (Gibbset al., 2011) and in thepathobiology
of AML (Irish et al., 2004). Additionally, attenuation of the IL-10/
pSTAT3 response—a response exhibited by mature immune
cells—was also a distinctive feature of IFPCs. Other signaling re-
sponses were strongly associated with primitive subpopulations
despite being less powerful for classification (Table S2).
Evaluating the ability of surface markers to identify IFPCs, it
was clear that no surface phenotype could be applied universally
across patients (Figure 6 and Figure S5A). CD34 was often an
important label for IFPCs, but in a subset of cases. For example,
CD34 marked both primitive and mature subpopulations in pa-
tient SJ03, where HLA-DR was a more specific marker of IFPCs
(p = 0.0007 versus p = 0.003, Student’s t test). In SJ05, where
CD34 expression was tightly associated with IFPCs (p = 7.4 3
108), the multiparameter surface measurements revealed that
CD123 was also an important marker (p = 4.4 3 106), whereas
CD123 did not identify IFPCs in SJ03. Patient SJ11 lacked CD34
expression almost entirely, as expected for this nucleophosmin-
mutated case (Taussig et al., 2010). In this patient, IFPCs were
distinctly labeled by elevated expression of CD47 (p = 7.1 3
106) and CD123 (p = 3.4 3 105). Surprisingly, we found that
CD34 expression can be strongly anti-correlated with primitive
signaling, as in patient SJ16, where CD34 expression was higher
in mature-signaling cells (p = 0.0027) and IFPCs were marked
instead by elevated expression of CD117 (p = 0.0026). Complete
median surface marker profiles for IFPC and non-IFPC subpop-
ulations are displayed in heat maps for each patient in Figures 6
and S5A.
Primitive Signaling Phenotype Identifies Clinically
Prognostic Gene Expression Signature
Ultimately, the importance of intratumor heterogeneity depends
on whether functionally distinct subpopulations influence clinical
outcomes, especially patient survival (Pearce et al., 2006). While
Figure 6. Leukemic Subpopulations with Primitive Signaling Exhibit Diverse Surface Phenotypes
Detailed surface and signaling phenotypes of IFPC subpopulations in four representative samples. Each row represents a particular patient using a number of
visuals. Biaxial dot plots (left) show the CD34/CD38 phenotype of IFPCs (red) in each sample. IFPCs displayed the canonical primitive CD34+/CD38mid phenotype
in only a subset of samples. The IFPCs displayed using the t-SNE landscape of Figure 3A (center; IFPCs in green, non-IFPCs inmaroon, healthy cells in gray). Heat
maps (right) display the signaling and surface phenotypes of all non-lymphoid subpopulations of each sample, stratified by IFPC classification (indicated by green
and maroon bars). Signaling responses are ordered as in Figure 5B. Signaling responses marked in bold with vertical lines were especially distinctive of IFPCs
(Main Text and Supplemental Experimental Procedures). See Figure S5A for all patients not shown here.our cohort was too small for survival analysis, genome-wide
expression arrays for 15 of our 16 patients were available from
a previous study (Radtke et al., 2009), providing a link to largercohorts for which gene expression and survival data were avail-
able. Because our samples displayed a wide range of IFPC fre-
quencies (Figure 5D), we reasoned that this variance could beCell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc. 193
Figure 7. Frequency of IFPCs Identifies a
Gene Expression Signature that Predicts
Clinical Outcome
(A) IFPC gene signature identified by deconvolu-
tion of bulk expression data using IFPC frequency.
The heat map displays expression of each gene in
the bulk measurements. Rows are alphabetically
ordered; columns are ordered by the mean
expression of the genes in the signature.
(B) The mean of the IFPC signature forms a clini-
cally significant prognostic indicator of overall
survival in 2 independent cohorts of adult AML
(Metzeler et al., 2008). Patients were assigned to
groups for Kaplan-Meier analysis based on
whether their IFPC expression score was below or
above the cohort median. p values obtained from
log-rank test.exploited to identify genes whose expression covaried with
these frequencies by in silico expression deconvolution (Lu
et al., 2003). As IFPC frequency varies across samples, genes
expressed specifically by these cells should be detectably
more or less abundant in the bulk gene expression measure-
ments, thereby providing an estimate of %IFPC in independent
samples from the level of this gene signature, measured in bulk.
We developed a deconvolution method based on linear
regression and cross-validation and used both %IFPC and %
SDPC to produce two gene expression signatures, containing
42 and 49 genes, respectively (see Experimental Procedures,
Figure 7A and Table S3). To characterize these signatures, we
queried the Molecular Signatures Database (Subramanian
et al., 2005) for significant annotations overlapping with each.
The SDPC signature—which contained CD34 among its top-
ranked genes—was highly enriched for gene sets associated
specifically with CD34+ AML (Table S3). Alternatively, the most
significant annotation for the IFPC signature was a set of genes
upregulated in CD133+ hematopoietic stem cells (Jaatinen et al.,
2006) (Q = 5.5 3 108; Table S3). CD133 marks healthy stem
cells that are possibly more primitive than CD34+ HSCs (Gal-194 Cell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc.lacher et al., 2000) and has been linked
to cancer stem cells in multiple cancer
types (Collins et al., 2005; O’Brien et al.,
2007). The mean expression of each
signature was highly correlated with its
corresponding subpopulation frequency
(Figure S6A), indicating that the signature
mean was an appropriate proxy for these
frequencies in independent cohorts.
We tested our signatures in two inde-
pendent cohorts of adult AML for which
both gene expression and survival data
were available (Metzeler et al., 2008).
While the SDPC signature was associ-
ated with survival in one cohort, this was
not replicated in the other (Figure S6B).
Alternatively, the IFPC signature was pre-
dictive of poor survival in both cohorts
(Figure 7B). Combining the data into asingle, large cohort (n = 242), the IFPC signature was highly pre-
dictive of poor survival (p = 4.83 106, Hazard Ratio [HR] = 3.4),
while the SDPC signature formed a less significant predictor (p =
0.005, HR = 1.6). To test these signatures against each other, we
placed them together in a bivariate Cox regression model. In
this setting, the IFPC signature retained its predictive power
(p = 8.2 3 105, HR = 3.0), while the SDPC signature became
completely uninformative for survival (p = 0.29, HR = 1.2).
We examined the relationship between the IFPC signature and
three signatures reported by (Eppert et al., 2011), which were
also developed to capture primitive gene expression programs
in AML. For each Eppert signature, we were able to reproduce
the significant correlation with survival in the data from Metzeler
et al. (2008). To assess the prognostic value of the IFPC signa-
ture when these other signatures were known, we tested three
bivariate Cox regression models in which each of the Eppert sig-
natures was used as a predictor alongside the IFPC signature
(Supplemental Experimental Procedures). The IFPC signature
proved to be a stronger predictor of survival than any of the Ep-
pert signatures (Table S3). In each model, the IFPC signature re-
tained significance (p < 0.005), while each Eppert signature
became statistically insignificant (p > 0.07). In a multivariate Cox
regression model containing all signatures (IFPC, SDPC, and the
Eppert signatures), only the IFPC signature retained significance
(p = 0.012, HR = 2.4; Table S3).
DISCUSSION
Tissues are complex populations of cells residing in phenotypi-
cally and functionally diverse states. A key challenge is to dissect
the high-dimensional structure of these complex populations
into components that can be studied individually and collec-
tively. In AML, where the relationship between phenotypic and
functional heterogeneity has been elusive, we usedmass cytom-
etry to profile both surface and signaling features simultaneously
in millions of leukemic cells.
PhenoGraph revealed a phenotypic landscape of a pediatric
AML cohort, providing a comprehensive overview of the major
phenotypes and an explicit characterization of intra- and intertu-
mor heterogeneity. The landscape resembled normal myeloid
development, but with aberrations resulting from malignant
accumulation of cells and neoplastic divergence from normal
phenotypes. However, this AML landscape was surprisingly
restricted to a limited repertoire of 14 MCs, each defined by
distinct surface marker patterns. Importantly, these MCs were
shared among a wide variety of AML genetic subtypes, yet ge-
netics had a detectable influence on the phenotypic composition
of each patient. Together these observations suggest the persis-
tence of developmental mechanisms that control the available
repertoire of phenotypes even in the context of genetic dysregu-
lation associated with cancer.
We used mass cytometry in conjunction with molecular inter-
rogation to construct signaling phenotypes that reflect differ-
ences in functional potential between subpopulations. Surface
and signaling phenotypes displayed tight coregulation in healthy
samples, whereas this coregulation was broken in AML. This
substantial decoupling of surface and signaling phenotypes in
the leukemic cells renders the surface markers typically used
in diagnostics unreliable proxies of cellular state and function
in AML.
Our demonstration that surface markers are unreliable re-
porters of signaling state in AML sheds light on the controversies
surrounding the LSC model, which rely on manual gating and
surface marker expression to define subpopulations. To avoid
the assumption that surfacemarkers indicate the functional state
of leukemic cells, we used healthy HSPCs to define a primitive
signaling phenotype, reflecting the functional state of undifferen-
tiated hematopoietic cells. We found that the primitive signaling
phenotype was present in most AML samples and could be used
to identify intratumor functional heterogeneity. Leukemic cells
displaying primitive signaling (Inferred Functionally Primitive
Cells [IFPCs]), were thereby identified using data-driven tech-
niques and without reference to surface phenotypes.
The IFPC phenotype was found to occur in most AML samples
at varying frequencies and with variable surface phenotypes,
often with low or absent CD34 expression. While no universal
surface phenotype captured IFPCs across patients, within
each patient IFPCs displayed homogeneous expression in
certain markers—markers whose importance was neither uni-versal nor unique. Our results suggest that a subset of leukemic
cells maintains a conserved, progenitor-like signaling program
that phenocopies the regulatory state of normal HSPCs, regard-
less of surface marker expression and underlying genetic
mutations.
Deconvolution analysis of microarray data identified a gene
expression signature associated with the IFPC phenotype that
can serve as a proxy for the frequency of this phenotype in a
given sample. This gene expression signature was enriched for
annotations related to primitive hematopoietic cells and included
genes—such as PROM1, SOCS2, and CD96—that have been
previously associated with healthy and/or leukemic stem cells
(Toren et al., 2005). Importantly, this gene expression signature
predicted survival in independent AML patient cohorts, suggest-
ing that this signaling-based definition describes a clinically rele-
vant cellular phenotype.
It was previously demonstrated (Eppert et al., 2011) that func-
tional characterization by physical sorting and xenotransplanta-
tion could be used to identify genes correlated with patient sur-
vival. Our analysis is conceptually related, but instead of
differential expression between sorted cells, we used in silico de-
convolution to identify genes, based on the measured cellular
frequencies of the IFPC phenotype. Ultimately, both approaches
seek to identify primitive cells by means that emphasize func-
tional over surface phenotypes, and to test whether the predom-
inance of primitive cells—approximated by expression of a gene
signature—is associated with poor survival.
Our findings were enabled by computational dissection of
intratumor heterogeneity. PhenoGraph creates a graph-based
model of cellular phenotypes, similar to that used previously to
identify developmental trajectories (Bendall et al., 2014) and in
this case defining phenotypes as communities of densely inter-
connected nodes. PhenoGraph is general and highly scalable
both in terms of dimensionality and sample size, making it suit-
able in a wide range of settings for which single-cell population
structure is of interest, including other cancers or healthy tissues,
and for use with other emerging single-cell technologies such as
single-cell RNA-seq. Many such cases are presented by the
tumor microenvironment, including drug-resistant tumor sub-
populations, infiltrating immune cells, and reactive stromal com-
ponents. These methods are also applicable to healthy tissues,
within which a large diversity of cell types remains uncharted.
Our signaling-based definition of primitive cells warrants
further investigation as it may indicate pathways that influence
the maturation of leukemic cells and could be leveraged thera-
peutically to block survival or direct differentiation. More broadly,
this molecular interrogation approach could be used to charac-
terize primitive cells in any cancer where a cognate healthy prim-
itive cell type is available to serve as a reference point. This study
provides a framework for interrogating and discovering other
features of cell biology that define network response states
and their associated mechanistic or clinical outcomes.EXPERIMENTAL PROCEDURES
Patient Samples
Sixteen (16) cryopreserved diagnostic bone marrow mononuclear cells
(BMMC) of pediatric AML patients were supplied by St. Jude Children’sCell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc. 195
Hospital (Memphis, TN) (Table S1). For healthy adult controls, cryopreserved
healthy BMMCs were purchased from AllCells (Emeryville, CA). All human
samples were obtained with informed consent in compliance with IRB-
approved protocols.
Mass Cytometry Analysis
Mass cytometry measurement and data pre-processing was performed as
previously described (Bendall et al., 2011; Finck et al., 2013; Zunder et al.,
2015). Surface marker expression was normalized based on the maximum in-
tensity observed in healthy samples, determined as the 99.5th percentile of the
3M healthy bone marrow cells. Data from all samples were divided by these
maximum values, yielding expression values that can be interpreted as x-fold
of the maximum observed in healthy. Mass cytometry data are publicly avail-
able at http://cytobank.org/nolanlab/reports. See Supplemental Experimental
Procedures for full details.
Microarray Data and Normalization
Matched Affymetrix U133A gene expression arrays for 15 pediatric AML
patients (Radtke et al., 2009) were downloaded from the Gene Expression
Omnibus (GEO: GSE14471). Gene expression and survival data for 242 cyto-
genetically normal adult AML patients from two independent cohorts (Metzeler
et al., 2008) were downloaded from the Gene Expression Omnibus (GEO:
GSE12417). All microarray data were processed and normalized as described
previously (Akavia et al., 2010).
The PhenoGraph Algorithm
PhenoGraph takes as input a matrix of N single-cell measurements and parti-
tions them into subpopulations by clustering a graph that represents their
phenotypic similarity. PhenoGraph builds this graph in two steps. First, it finds
the k nearest neighbors for each cell (using Euclidean distance), resulting in N
sets of k-neighborhoods. Second, it operates on these sets to build a weighted
graph such that the weight between nodes scales with the number of neigh-
bors they share. The Louvain community detection method (Blondel et al.,
2008) is then used to find a partition of the graph that maximizes modularity.
See Supplemental Experimental Procedures for full details on the method
and an assessment of its accuracy, efficiency, and robustness compared to
other methods. Source code for PhenoGraph is available online for MATLAB
and Python (www.c2b2.columbia.edu/danapeerlab/html/software.html).
PhenoGraph Classification
Given a dataset of N d-dimensional vectors, M distinct classes and a vector
providing the class labels for the first L samples, the PhenoGraph classifier as-
signs labels to the remaining N  L unlabeled vectors. First, a graph is con-
structed as described above. The classification problem then corresponds
to the probability that a random walk originating at unlabeled node x will first
reach a labeled node from each of the M classes. This defines an M-dimen-
sional probability distribution for each node x that records its affinity for each
class. See Supplemental Experimental Procedures for full details on this
method, as well as an evaluation of its performance on benchmark data.
Applying PhenoGraph and SARA to AML Cohort
We ran PhenoGraph on each sample individually, defining subpopulations
based on expression of the 16 surface markers. For each sample, all ex vivo
conditions were pooled, as we previously demonstrated that surface marker
distributions are not altered by these short-term perturbations (Bendall et al.,
2011). PhenoGraph was run on the normalized surface phenotype matrices
for each sample, with the parameter k = 50.
Subpopulation signaling phenotypes were computed for each cluster using
SARA, followed by Z score standardization. See Supplemental Experimental
Procedures for full details.
Defining AML Metaclusters
Each AML subpopulation was represented by its centroid, resulting in a 4253
16 matrix. PhenoGraph was run on 425 subpopulation centroids with the
parameter k = 15, resulting in 14 metaclusters (MCs) delineating the major
cohort phenotypes. These MCs are a robust feature of the data and remained
consistent when the metaclustering was performed on subsets of patients196 Cell 162, 184–197, July 2, 2015 ª2015 Elsevier Inc.(Supplemental Experimental Procedures and Figure S3B). To characterize
these MCs, we systematically matched cells from healthy bone marrow (H1–
H5) with the MC surface marker profiles using linear discriminant analysis.
See Supplemental Experimental Procedures for full details.
PhenoGraph Classification of Leukemic Subpopulations
We used the PhenoGraph classifier to classify leukemic subpopulations
based on training examples provided by the healthy subpopulations. Using
similarities derived either from surface or signaling phenotypes, k-neighbor
graphs (k = 15) were constructed over 616 subpopulations (healthy and
leukemic). Specifically, we used a weighted Euclidean distance in which
each phenotypic feature was weighted according to its statistical association
with known cell types in the healthy samples. Each AML subpopulation was
classified based on its phenotypic proximity to the healthy training exam-
ples. Classification was performed using surface and signaling classifiers
separately, resulting in two alternative classifications per AML subpopulation
(Figures 6 and S4B). See Supplemental Experimental Procedures for full
details.
Gene Expression Signatures and Survival Analysis
For each score, %SDPC or %IFPC, a set of associated genes was defined
based on correlation with the expression patterns across patients, using
linear regression. This in silico gene expression deconvolution assumes that
changes in bulk expression of certain genes will track with changes in subpop-
ulation frequency. We used leave-two-out cross-validation across 15 patients
to select genes that placed in the top one percentile and had a SD across
subsets < 5%.
We used gene expression and survival data for 242 cytogenetically normal
adult AML patients from two independent cohorts (Metzeler et al., 2008). For
each patient, the frequency of a cell type (%IFPC or %SDPC) was estimated
as the mean expression intensity of the associated gene signature. For
Kaplan-Meier analysis, patients were stratified into two groups based on the
median expression value of the signature of interest. See Supplemental Exper-
imental Procedures.
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